Cancer-associated Thrombosis
8
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
38%
3 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
The Gynecological Cancer Associated Thrombosis (GynCAT) Study
A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer